The Combination of Anti-CD22 Immunotoxins with Standard Chemotherapeutic Agents on a Human Burkitt Lymphoma Cell Line
Posted Jun 15 2010 5:00pm
Description of Invention: The treatment of hematological malignancies has been a major public health challenge because patients frequently do not respond to conventional therapies with long-term complete remission. However, current therapies are associated with multiple toxicities, suggesting that new therapies are needed.
In the past several years immunotoxins have been developed as an alternative approach to treat different malignancies. Since hematological malignancies are readily accessible via the blood stream, immunotoxins represent a viable therapeutic approach. Furthermore, immunotoxins have the potential for decreased nonspecific toxicity, suggesting these agents could lead to improved cancer therapies.
This technology relates to new combination therapies using an immunotoxin and chemotherapeutic agent. Specifically, the anti-CD22 immunotoxin HA22 has been used in combination with 4 different chemotherapeutic agents: Taxol, cisplatin, etopside and doxorubicin. The combinations were shown to have a synergistic effect when examined in both in vitro cell models and in vivo animal models. As a result, it may be possible for this combination therapy to overcome previous short comings seen with chemotherapy treatment alone.
Applications: Treatment of cancers associated with the increased expression of CD22, such as leukemia and lymphoma.
Uses a combination of agents previously shown to be effective in killing cancer cells
Combination of immunotoxins and chemotherapeutics showed a synergistic effect, suggesting the combination offers distinct advantages of the use of either agent alone
Portfolios: Cancer Cancer - Therapeutics In-vivo Data In-vitro Data
For Additional Information Please Contact: David Lambertson Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4632 Fax: 301-402-0220